TARA stock is currently trading at $3.745, showing a strong upward trend with a 10.32% gain in the last trading session. The bullish view is driven by positive Phase 2 trial results for TARA-002 targeting invasive bladder cancer, which significantly boosts investor confidence in its pipeline. With a year-to-date gain of over 180% in 2024, the stock has potential to test resistance levels near $4.23, supported by momentum from clinical developments.